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Abstract
There are convincing data to show that the consequences of a severe infection extend well beyond the first month following it. During the
first year after severe sepsis or infection, the survival of sepsis patients is guarded compared with matched control groups. Their quality of
life is impaired, and they suffer from rapid degradation in cognition and functional capacity. We could postulate three explanations for the
long-term bad outcomes of severe infections and sepsis (or a combination of the three): (i) sepsis usually happens in the elderly and sick, and
it causes deterioration in life expectancy and functional status as an acute, non-specific event; (ii) an interaction between specific
mechanisms of sepsis and underlying disorders; or (iii) long-term complications directly related to infection. If the second or third
explanations are true, then management of the original infection/sepsis might have an influence on long-term outcomes. Elderly survivors of
severe infections should be carefully assessed for whether they need intermediate care for recuperation and re-conditioning when leaving
hospital. We need prospective, observational studies to define which are the factors that most influence long-term outcomes, and especially
management of the acute infection. The investigation of long-term outcomes in trials of treatment modalities for sepsis or severe infections
should be encouraged. The true answer for whether one treatment is better than another in severe infections or sepsis lies in the people
trajectory in the year following the infection, and not only on 4–6 weeks outcome.
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We believe that but for a few exceptions acute severe
infection is a sharply defined event, and with recovery the
patient is back on the same health and quality of life trajectory
as before. This belief is reflected in the short horizon of
time for measuring outcomes in most trials and observational
studies: death or failure of treatment within 4–6 weeks. For
a large group of patients this belief is unfounded. There
are convincing data to show that the consequences of a
severe infection extend well beyond the first month follow-
ing it.
We have compared a group of 1991 patients with
bacteraemia or fungaemia to a control group of 1991
inpatients without any bacterial or fungal infections, matched
for age, sex, department, date of admission and underlying
disorders [1]. In the patients with bacteraemia, the mortality
rate was 26% at 1 month, 48% at 1 year, and the median
survival was 16.2 months. In the control group, the mortality
rate was 7% at 1 month, 27% at 1 year, and median survival
was  75 months (p <0.001, log-rank test). Factors signifi-
cantly and independently associated with worse survival in
patients with bacteraemia were septic shock, inappropriate
empirical antibiotic treatment, nosocomial infection, low
serum albumin, high serum creatinine, low functional class,
advanced age and malignancy. Similar results were shown by
Lillie et al. [2] in a cohort of 304 patients with bacteraemia.
Quartin et al. [3] constructed a proportional hazards model
for long-term survival from the demographic and illness
characteristics of a control population of 91 830 non-psychi-
atric, non-infected patients. They then examined survival in
1505 patients with sepsis, and the patients’ mean lifespan was
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reduced from a predicted 8 years to 4 years among 30-day
survivors. The long-term survival in 30-day survivors of sepsis
was influenced by the severity of their sepsis.
Important outcomes other than survival were affected as
well. In a cohort of old patients with Staphylococcus aureus
bloodstream infections, 54% of community-dwelling patients
who survived hospitalization needed subacute care after
discharge [4]. In a group of 30 survivors of severe sepsis, the
quality of life as assessed at an average of 17 months after
hospital discharge was significantly lower than that of the
general population [5]. Survivors of sepsis had, during a long
follow up, a lower body mass index than old people, or than
expected from their own pre-sepsis trajectory (but not higher
incidence of falls, incontinence or visual or hearing loss) [6].
Iwashyna et al. [7] compared 516 survivors of severe sepsis
with 4517 survivors of hospitalizations that did not involve
sepsis. The prevalence of moderate to severe cognitive impair-
ment increased from 6% before the sepsis to 17% after severe
sepsis. Patients also experienced a significant deterioration in
functions of daily living, and these functions continued to
deteriorate rapidly in the years following sepsis. The deterio-
ration in cognition and functional status were significantly worse
following sepsis than following hospitalization for a different
reason. Interestingly, sepsis did not increase symptoms of
depression [8]. In a large, retrospective cohort of sepsis
survivors Weycker et al. [9] found a guarded 5-year prognosis,
but also high medical care charges for the years following sepsis.
Winters et al. [10] conducted a systematic review on long-
term mortality and quality of life following sepsis and septic
shock. Their search (up to 2009) identified 30 studies that
reported mortality or quality of life at least 90 days after
discharge. In all studies that compared long-term survival in
septic patients with that in a control population, the survival in
sepsis was lower. Similar results were noted for quality of life.
The results did not depend on the design of the study or
sample size. It held true for studies including patients with
severe sepsis as well as studies addressing patients with less
severe sepsis.
Although the observations are convincing, they do not
supply a reason for the long-term consequences of sepsis. We
could postulate three explanations (or a combination of the
three). (i) Sepsis usually happens in the elderly and sick, and it
causes deterioration in life expectancy and functional status as
an acute, non-specific event. (ii) An interaction exists between
specific mechanisms of sepsis and underlying disorders. (iii)
Long-term complications are directly related to infection, e.g.
metastatic infections; or late infections with resistant patho-
gens or with fungi; or Clostridium difficile infections. Differen-
tiating between the three explanations might have practical
implications. If the second or third explanations are true, then
management of the original infection/sepsis might have an
influence on long-term outcomes.
We have a few indications that the characteristics of
infection and its management might influence long-term
outcomes. Survival curves for patients given appropriate
antibiotic treatment continue to diverge from those of patients
given inappropriate treatment even after months [1]. Long-
term survival was influenced by the severity of the original
sepsis [2]. In 50 children discharged from hospital after septic
shock, 44% had cognitive scores below the lowest quartile of
the healthy population [11].
In one study [12], long-term outcomes were worse for
patients with polymicrobial infections. Jensen et al.[13] found
that during 1 year, 9% of patients with an episode of
bacteraemia had a recurrent episode. Risk factors for recur-
rence of bacteraemia were a high Charlson comorbidity score;
nosocomial or healthcare-associated bacteraemia; polymicro-
bial or fungal infection; and urogenital focus of infection.
Recurrent bacteraemia was associated with a higher risk for
1-year mortality with significant odds ratio 3.6, 95% confidence
interval 3.1–4.0.
Weinberger et al.[14] showed an increase in age-standard-
ized mortality ratios for patients with non-typhoid Salmonella
infections. Age, extra-intestinal source of isolation and specific
serotypes were identified as risk factors for long-term
mortality. Studies in humans [15,16] and animals [17,18] have
pointed to possible pathways by which sepsis can influence
long-term changes in cognition.
Long-term effects of sepsis and severe bacterial infections
have clinical implications. Elderly survivors of severe infections
should be carefully assessed for whether they need interme-
diate care for recuperation and re-conditioning when leaving
the hospital (akin to what is done now with patients following
myocardial infarction or brain infarct). Survivors of sepsis are a
large and growing group, and the additional resources
demanded to take care of long-term consequences of sepsis
should be explicitly taken into account [19].
We need additional research. In prospective, observational
studies we should ask which are the factors that most
influence long-term outcomes: whether severity of sepsis;
organ failure; involvement of specific organs in sepsis; specific
pathogens or sources of infection; interactions between
underlying disorders and features of infections and sepsis. An
interesting subgroup are young adults and children with no
underlying disorders. We need to look carefully at recurrent
bacteraemia, late presentation of metastatic foci of infection,
resurgence of the original infection, subsequent fungal infec-
tions or infections with resistant pathogens, and Clostridium
difficile colitis. Most importantly, we should ask whether
features of management and treatment affect long-term
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outcomes: timing and appropriateness of antibiotic treatment;
haemodynamic support; psychoactive drugs; nutrition; or
others. There are even some leads that can direct research
into the underlying mechanisms [15–18].
The investigation of long-term outcomes in trials of
treatment modalities for sepsis or severe infections should
be encouraged. Albeit adding to costs, the true answer of
whether one treatment is better than another in severe
infections or sepsis, especially in elderly people, lies in the
trajectory of outcomes for these patients in the year following
the infection, and not only in the first 4–6 weeks.
Funding
The review was written as part of routine work.
Transparency Declaration
The author has no conflict of interest to declare.
References
1. Leibovici L, Samra Z, Konigsberger H, Drucker M, Ashkenazi S, Pitlik
SD. Long-term survival following bacteremia or fungemia. JAMA 1995;
274: 807–812.
2. Lillie PJ, Allen J, Hall C et al. Long term mortality following bloodstream
infection. Clin Microbiol Infect 2012; E-pub ahead of print: DOI: 10.1111/
1469-0691.12101.
3. Quartin AA, Schein RMH, Kett DH, Peduzzi PN. Magnitude and
duration of the effect of sepsis on survival. JAMA 1997; 277: 1058–1063.
4. Malani PN, Rana MM, Banerjee M, Bradley SF. Staphylococcus aureus
bloodstream infections: the association between age and mortality and
functional status. J Am Geriatr Soc 2008; 56: 1485–1489.
5. Heyland DK, Hopman W, Coo H, Tranmer J, McColl MA. Long-term
health-related quality of life in survivors of sepsis. Short Form 36: a
valid and reliable measure of health-related quality of life. Crit Care Med
2000; 28: 3599–3605.
6. Iwashyna TJ, Netzer G, Langa KM, Cigolle C. Spurious inferences about
long-term outcomes: the case of severe sepsis and geriatric conditions.
Am J Respir Crit Care Med 2012; 185: 835–841.
7. Iwashyna TJ, Ely EW, Smith DM, Langa KM. Long-term cognitive
impairment and functional disability among survivors of severe sepsis.
JAMA 2010; 27: 304.
8. Davydow DS, Hough CL, Langa KM, Iwashyna TJ. Symptoms of
depression in survivors of severe sepsis: a prospective cohort study of
older Americans. Am J Geriatr Psychiatry 2012. [Epub ahead of print].
9. Weycker D, Akhras KS, Edelsberg J, Angus DC, Oster G. Long-term
mortality and medical care charges in patients with severe sepsis. Crit
Care Med 2003; 31: 2316–2323.
10. Winters BD, Eberlein M, Leung J, Needham DM, Pronovost PJ,
Sevransky JE. Long-term mortality and quality of life in sepsis: a
systematic review. Crit Care Med 2010; 38: 1276–1283.
11. Bronner MB, Knoester H, Sol JJ, Bos AP, Heymans HS, Grootenhuis
MA. An explorative study on quality of life and psychological and
cognitive function in pediatric survivors of septic shock. Pediatr Crit
Care Med 2009; 10: 636–642.
12. Laupland KB, Svenson LW, Gregson DB, Church DL. Long-term
mortality associated with community-onset bloodstream infection.
Infection 2011; 39: 405–410.
13. Jensen US, Knudsen JD, Wehberg S, Gregson DB, Laupland KB. Risk
factors for recurrence and death after bacteraemia: a population-based
study. Clin Microbiol Infect 2011; 17: 1148–1154.
14. Weinberger M, Yaron S, Agmon V, Yishai R, Rosenberg A, Peretz C.
Curtailed short-term and long-term survival following infection with
non-typhoid Salmonella in Israel. Clin Microbiol Infect 2011; 17: 278–
284.
15. Semmler A, Widmann CN, Okulla T et al. Persistent cognitive
impairment, hippocampal atrophy and EEG changes in sepsis survivors.
J Neurol Neurosurg Psychiatry 2013; 84: 62–69.
16. Streck EL, Comim CM, Barichello T, Quevedo J. The septic brain.
Neurochem Res 2008; 33: 2171–2177.
17. Chavan SS, Huerta PT, Robbiati S et al. HMGB1 mediates cognitive
impairment in sepsis survivors. Mol Med 2012; 18: 930–937.
18. Semmler A, Frisch C, Debeir T et al. Long-term cognitive impairment,
neuronal loss and reduced cortical cholinergic innervation after
recovery from sepsis in a rodent model. Exp Neurol 2007; 204: 733–
740.
19. Iwashyna TJ, Cooke CR, Wunsch H, Kahn JM. Population burden of
long-term survivorship after severe sepsis in older Americans. J Am
Geriatr Soc 2012; 60: 1070–1077.
ª2013 The Author
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 19, 510–512
512 Clinical Microbiology and Infection, Volume 19 Number 6, June 2013 CMI
